Articles tagged with Adoptive T Cell Therapy
Scientists at Gladstone Institutes and UCSF discovered a pair of genetic edits that make CAR-T cells more effective against solid tumors. The new CRISPR screening platform enables the study of gene edits on CAR-T cells inside living mice, uncovering therapeutic targets previously missed in conventional cell culture systems.
The University of Colorado Anschutz Gates Institute has achieved first-in-U.S. FDA clearance for a novel CAR T-cell therapy targeting aggressive leukemia cells, representing a potential new treatment approach for patients with hard-to-treat disease. The therapy will be evaluated in a Phase 1 clinical trial starting this summer.
Researchers developed a biomimetic platform to enhance CAR T cell therapy against leukemia by creating a molecular bridge that reinforces the interface between CAR T cells and leukemia cells. This platform, called FACE, uses ferritin to bind to CD71 on leukemia cells, improving cell recognition and elimination.
CAR T-cell therapy is now available for eligible primary CNS lymphoma patients, thanks to Dana-Farber-led research. The FDA label update removes a prior exclusion and may expand treatment options for relapsed or refractory patients.
Five IIT researchers receive Proof-of-Concept grants to develop innovative health technologies, including a smart microscope and edible pills. These projects aim to tackle cancer, dyslexia, and diagnostics with cutting-edge technologies like quantum computing and near-infrared photonic chips.
The ESMO Immuno-Oncology Congress 2025 will discuss key developments in immuno-oncology, including combined approaches, AI in cancer therapy, and innovative strategies across various cancers. The congress aims to advance the field of immunotherapy and improve patient outcomes.
Scientists have discovered that CD4 T cells can target tumour cells with high efficiency, expanding the pool of patients who could benefit from this therapy. A clinical trial is currently preparing to test this approach in adults and children with various types of cancer.
Researchers at Nagoya University have created CAR-T cells that recognize and target the Eva1 protein on cancer cells, effectively eliminating tumors in lab mice. The treatment is designed to be safer by ignoring healthy cells with low amounts of Eva1.
Researchers identified a link between the loss of Y chromosome in white blood cells and reduced ability to kill cancer cells. This finding may explain why men with loss of Y have higher cancer risks and poorer outcomes. The study provides insights into how this genetic change affects immune system function.
Scientists at Goethe University Frankfurt have discovered a new way to tailor natural killer cells to target leukemia cells, improving their efficacy. The researchers used CRISPR/Cas9 gene editing to disable an immune checkpoint, allowing the modified cells to attack cancer cells more effectively.
Researchers have discovered that sodium chloride can increase the efficiency of antitumoral T cells, leading to improved metabolic fitness and enhanced tumor killing capabilities. This finding has significant implications for adoptive T-cell therapy in cancer treatment.
Researchers at TUM have uncovered a mechanism by which tumor cells prevent the formation of immune responses, including cytotoxic T cells. This discovery provides rationales for new cancer immunotherapies and could enhance existing treatments.
Researchers at the University of Pittsburgh have discovered how to overcome resistance to conventional immunotherapies in metastatic uveal melanoma. They developed a clinical tool called Uveal Melanoma Immunogenic Score (UMIS) to predict patient response and improve treatment outcomes.
Researchers at Institute for Systems Biology have made a breakthrough discovery about T cells, finding that the genetically encoded T-cell receptor sequence determines a T cell's function. This fundamental discovery has huge potential for developing custom immune responses to specific antigens.
Researchers successfully deployed CAR-T therapy in a mouse model of ovarian cancer, demonstrating strong anti-tumor effects even at late stages. The treatment was highly effective, shrinking or eliminating tumors after just one dose and continuing to work for months without major side effects.
A novel biomaterials-based approach enhances adoptive T cell therapy with cancer vaccine technology, providing strong and long-lasting effects against solid tumors. In mice carrying melanomas, SIVET enables fast tumor shrinking and long-term protection.
Researchers have discovered a non-invasive way to isolate tumor-reactive lymphocytes from blood, opening up new treatment options for cancer patients. This breakthrough could potentially bypass radiation therapies and harsh chemotherapy drugs, making it a more viable option for hospitals.
Researchers have developed a new safety system for CAR-T cells, called VIPER CAR-T cells, that can be turned on or off. This allows doctors to target cancer more aggressively while minimizing side effects. The new system uses an FDA-approved antiviral drug to control the cell's activity.
Scientists have developed a novel therapy that reprograms the metabolism of tumor cells, increasing their level of reactive oxygen species and leading to death. By pushing oxidative stress levels to the point where cancer cells become deadly, this treatment shows promise in treating various types of cancer.